TELO
Income statement / Annual
Last year (2024), Telomir Pharmaceuticals, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Telomir Pharmaceuticals, Inc. Common Stock's net income was -$16.53 M.
See Telomir Pharmaceuticals, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.24 M
|
$1.57 M
|
$833.21 K
|
$126.49 K
|
| General & Administrative Expenses |
$9.64 M
|
$600.19 K
|
$20.94 K
|
$11.64 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.64 M
|
$600.19 K
|
$20.94 K
|
$11.64 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$11.87 M
|
$3.94 M
|
$854.15 K
|
$138.13 K
|
| Cost And Expenses |
$11.87 M
|
$3.94 M
|
$854.15 K
|
$138.13 K
|
| Interest Income |
$48.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$4.34 M
|
$1.64 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
-$7.49 M
|
$854.15 K
|
$138.13 K
|
| EBITDA |
-$12.19 M |
-$11.43 M |
-$854.15 K |
-$138.13 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$4.29 M
|
-$9.13 M
|
$0.00
|
$0.00
|
| Income Before Tax |
-$16.53 M
|
-$13.07 M
|
-$854.15 K
|
-$138.13 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$854.14 K
|
-$138.13 K
|
| Net Income |
-$16.53 M
|
-$13.07 M
|
-$854.15 K
|
-$138.13 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
| EPS |
-0.56 |
-0.44 |
-0.0288 |
-0.0047 |
| EPS Diluted |
-0.56 |
-0.44 |
-0.0288 |
-0.0047 |
| Weighted Average Shares Out |
$29.54 M
|
$29.61 M
|
$29.61 M
|
$29.61 M
|
| Weighted Average Shares Out Diluted |
$29.54 M
|
$29.61 M
|
$29.61 M
|
$29.61 M
|
| Link |
|
|
|
|
